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Abstract 
Purpose 
The objective of this study was to compare the effects of two types of enteral 
supplements, an antioxidant-enriched enteral nutrition (AeEN) and an 
immune-enhancing enteral nutrition (IeEN), on the nutrition, immunoinflammatory 
response, antioxidant capacity and clinical outcomes in patients after esophagectomy 
for cancer. 
Methods 
Patients (n=20) undergoing esophagectomy for cancer were randomized in this 
single-center, open-label study. Two types of enteral supplements were used for five 
days before surgery and seven days after surgery. The circulating levels of nutritional 
markers, immunoinflammatory markers, oxidative stress markers, and the antioxidant 
capacity were compared throughout the perioperative period, and the patients’ clinical 
outcomes were also compared.   
Results 
The circulating levels of nutritional markers decreased after surgery, but the changes 
were not significantly different between the AeEN group and the IeEN group 
throughout the perioperative period. Surgery increased the immunoinflammatory 
markers, and the levels were not significantly different between the groups after 
surgery. Surgery also increased the levels of oxidative stress markers, but there were no 
significant differences between the groups throughout the study period.  
Conclusions 
  The results of this pilot study suggest that AeEN and IeEN have a similar effect on 
nutrition, the immunoinflammatory response, antioxidant capacity and clinical 
outcomes after esophagectomy for cancer. These findings therefore warrant further 
studies on a larger scale.
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Introduction 
 
  In the past ten years, there have been many reports concerning the efficacy of 
immune-enhancing nutrients (IeNs) including arginine, omega-3-unsaturated fatty 
acids, nucleotides and other molecules used prior to gastrointestinal surgery (1-4). The 
immune-enhancing enteral nutrition (IeEN) is considered to increase the immune 
response and improve the surgical outcomes, such as mortality and morbidity, the 
length of the intensive care unit (ICU) stay, the length of the hospital stay, and other 
outcomes. Impact® includes supplemental arginine, omega-3-unsaturated fatty acids, 
nucleotides, and is specialized as IeEN. We have previously reported a retrospective 
study that showed that the Impact® IeEN reduced the duration of systemic 
inflammatory response syndrome (SIRS) and the morbidity after esophagectomy for 
cancer (5). According to the consensus recommendations of the American Society for 
Parenteral and Enteral Nutrition (ASPEN), the preoperative use of IeEN offers a 
benefit for patients undergoing elective gastrointestinal surgery, such as esophagectomy 
(6). In the guidelines on enteral nutrition of the European Society for Clinical Nutrition 
and Metabolism (ESPEN), the perioperative management is focused on the enhanced 
recovery of patients after surgery (ERAS). According to those guidelines, the 
preoperative use of enteral nutrition including immunomodulatory substances is 
recommended for cancer patients undergoing major upper abdominal surgery (7).  
  A variety of diseases are recognized to be related to oxidative stress resulting from an 
imbalance between oxidants produced by various stresses and the natural antioxidant 
capacity. The overproduction of reactive oxygen species (ROS) arising from 
inflammation due to stresses such as surgery, trauma, burns and other causes, as well 
as in life-style-related diseases, can cause damage to cells. Accordingly, it is hoped that 
antioxidants can reduce the oxidative stress and the subsequent organ damage (8). 
There was a report that indicated that antioxidant-enriched enteral nutrition (AeEN) 
increased the immune response in patients undergoing major gastrointestinal surgery 
(9). In contrast, there was another report that the AeEN including glutamine and an 
antioxidant solution did not improve the prognoses of burned and major trauma 
patients (10), and that AeEN including an antioxidant, and vitamins A, C, and E 
improved the blood level of antioxidants, but did not improve the clinical outcomes (11). 
The Anom® AeEN includes antioxidants such as catechin and proanthocyanidin. It also 
includes arginine, omega-3-polyunsaturated fatty acids and nucleotides. 
   The purpose of this prospective randomized trial was to compare the effects of AeEN 
(Anom○R ) and IeEN (Impact○R ) on the nutritional markers, immunoinflammatory 
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markers, antioxidant capacity and clinical outcomes in patients undergoing 
esophagectomy for cancer.  
 
Methods 
 
  During the period from June 2007 to June 2009, 20 patients were enrolled in this trial 
who met the following conditions; 1) younger than 75 years of age, 2) 
potentially-resectable esophageal cancer of clinical stage II-III, 3) no pretreatment, 4) 
possible peroral intake, 5) proposed operation being right-sided transthoracic 
esophagectomy and esophageal reconstruction using a gastric conduit, and 6) the 
informed consent provided. They were randomly divided into two groups: an of AeEN 
group that received Anom® an IeEN group that received Impact®. The elements per 
100 ml of Anom® and Impact® are described in Table 1. Both formulas included the 
basic nutrients such as protein, fat and carbohydrates. They both also contained 
immune-enhancing nutrients such as arginine, omega-3-polyunsatuilated fatty acids 
and nucleotides. However, the levels of such nutrients were much higher in the Impact® 
than in the Anom® supplement. On the other hand, glutamine and antioxidants, such 
as catechin and proanthocyanidin, were included in the Anom®, but not in the Impact® 
supplement.  
Both nutrient supplements were administered according to the standard Clinical 
Pathway (Figure 1). In the AeEN group, 800 ml of Anom® were given perorally for five 
days before surgery at a total dose of 4,000 ml, while in the IeEN group, 750 -1,000 ml of 
Impact® were given perorally for five days before surgery for a total dose of 4000 ml. 
For seven days after surgery, Anom® (from 400 ml to 1,600 ml) was given using a 
gastrostomy at a total dose of 8,400 ml, while in the IeEN group, Impact® (from 500 ml 
to 1,500 ml) was given using a gastrostomy for a total dose of 8,500 ml. All the protocols 
were approved by the institutional review board of the Kurume University School of 
Medicine (#06058: 29th September, 2006), and all the patients provided informed 
consent for their participation in this trial. 
The patients’ demographic information, such as their age, gender, body weight and 
body mass index (BMI) on admission, diet on admission, co-morbidities, the clinical and 
pathological TNM stages (UICC 7th ed.)(12), surgical procedures, and the length of the 
operation and blood loss were not significantly different between the AeEN group and 
the IeEN group (Tables 2-3). All the patients underwent right-sided transthoracic 
esophagectomy with thoracoabdominal two-field or cervicothoracoabdominal three-field 
lymphadenectomy, followed by esophageal reconstruction using a gastric conduit. The 
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route of esophageal reconstruction was a retrosternal route in one patient and a 
subcutaneous route in the other nine patients in the AeEN group, while it was a 
subcutaneous route in all ten patients in the IeEN group. None of the patients 
underwent a perioperative blood transfusion, although all of the patients had 
autotransfusions of 800 ml prepared in case a transfusion was necessary. Enteral 
nutrition was not discontinued in any patient, although abdominal distension was 
observed in two patients in the IeEN group.   
The patients’ body weight and the BMI were measured seven and one day before 
surgery, and on the first, third, seventh and thirteenth days after surgery. As 
nutritional markers, the levels of serum protein, albumin, transferrin and retinol 
binding protein (RBP) were measured seven and one day before surgery and on the 
seventh and thirteenth days after surgery. As immunoinflammatory markers, the WBC, 
C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) level were 
measured. The WBC and CRP level were measured seven and one day before surgery 
and days after surgery. IL-6 and IL-8 were measured immediately and on the first and 
second days after surgery. As oxidative stress markers, the urinary levels of 
8-hydroxy-2’-deoxyguanosine (8OHdG), an oxidized nucleotide, and 8-Isoprostane, an 
oxidized lipid, were measured, and the potential antioxidant (PAO) level in the serum 
was measured as an indicator of the antioxidant capacity. These three parameters were 
measured seven and one days before surgery and on the second and thirteenth days 
after surgery.  
The incidence of postoperative complications, the length of SIRS, the length of 
hospital stay, nutritional markers, immunoinflammatory markers and the antioxidant 
capacity were compared between the two groups. SIRS was defined as fulfilling at least 
two of the following four conditions; (1) body temperature > 38℃ or < 36℃, (2) pulse >  
90/min, (3) respiration > 20/min, PaCO2 < 32 mmHg or need for assisted ventilation, (4) 
WBC > 12,000/mm3 or < 4,000/mm3. The length of hospital stay was defined as the 
duration until the initiation of postoperative chemotherapy and/or radiotherapy in 
patients receiving adjuvant therapy.  
The Wilcoxon-Mann-Whitney test was used to examine the differences between the 
AeEN group and the IeEN group at the initial time point of measurements with a 5% 
level of significance. The difference between the two groups after the initial time point 
were analyzed by examining theβ2 in the following model that was adjusted for the 
difference in the measurements at the previous time point.  
y=β0 +β1 (the previous value) + β2 (group) + γ(the previous value)(group)   
The p-values at several time points after the initial measurement were summarized 
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using summary statistics which were constructed by addingβ2 at those time points. 
Since the absolute sizes of the two groups were fairly small for conventional statistical 
tests with a 5% level of significance, the Akaike Information Criterion (AIC) which 
chose the most reasonable model based on the Kullback-Libler Information (13) was 
employed except for the test at the initial point; this was determined by simple 
computation to indicate the equivalence of the two groups if the p-value was > 0.18 and 
no equivalence if the p-value was < 0.18.  
 
Results 
 
  The changes in the body weight and the BMI are shown in Figure 2. Both values were 
increased for several days after surgery and decreased to the preoperative level within a 
week. No differences were observed in the perioperative changes in the body weight and 
BMI between the two groups, except for the thirteenth day after surgery when they 
were higher in the IeEN group.  
  The changes in the nutritional markers, such as protein, albumin, transferrin and 
RBP levels appear were in Figure 3. The levels of the nutritional markers were 
increased by the preoperative administration of the nutrients for five days in both 
groups, and they decreased after surgery, and then increased again by the postoperative 
administration of the nutrients for seven days in the both groups. The total protein level 
was higher on the seventh day after surgery in the IeEN group, while it was higher on 
the thirteenth day after surgery in the AeEN group. The transferrin level was higher on 
both the seventh and thirteenth days after surgery in the IeEN group. However, no 
significant differences were found overall in any of the four nutritional markers 
between the groups. In short, no differences were observed in the nutritional markers 
between the AeEN group and the IeEN group through the period from seven days before 
surgery to the thirteenth day after surgery. 
  Figure 4 shows the changes in immunoinflammatory markers such as the WBC and 
the CRP, IL-6 and IL-8 levels. All of these markers were increased after surgery; 
however, IL-6 and IL-8 rapidly decreased by the day after surgery, and the CRP level 
slowly decreased for one or two weeks. The WBC remained high for two weeks after 
surgery. The WBC was high in the AeEN group on the first and thirteenth days after 
surgery, while it was higher in the IeEN group on the seventh day after surgery. The 
CRP level was higher in the AeEN group on the seventh day after surgery. In addition, 
overall CRP level was significantly higher in the AeEN group. No significant differences 
were found in the levels of IL-6 and IL-8 between the groups at any point or overall. In 
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short, only the level of CRP was significantly different between the two groups, being no 
difference was observed in the inflammatory markers between the AeEN group and the 
IeEN group throughout the period after surgery, except for CRP which was more 
reduced in the IeEN.   
  Figure 5 shows the changes in the oxidative stress, as indicated by 8OHdG and 
8-Isoprostane in the urine, and that of the antioxidant capacity, as determined by the 
PAO level in the serum. The levels of oxidative stress markers were increased after 
surgery, while the antioxidant capacity was decreased after surgery. The levels of 
8OHdG in the urine were higher in the IeEN group on the thirteenth day after surgery, 
and the overall level was higher in the IeEN group. No differences were found in the 
8-Isoprotane in urine or in the PAO in serum between the groups at any point after 
surgery or overall. In short, no difference was observed in the levels of the oxidative 
stress marker, 8-Isoprostane, or in the antioxidant capacity (based on the PAO) between 
the AeEN and IeEN groups, although the level of 8OHdG (another marker of oxidative 
stress) was found to have decreased to a greater extent by the AeEN.  
  As shown in Table 3, the mean and median the length of SIRS after surgery were 
1.8±1.5 days and one day, respectively, in the AeEN group, while these were 3.4±3.5 
days and one day, respectively, in the IeEN group. No significant difference was found in 
the length of SIRS between the groups. The mean and median length of hospital stay 
after surgery were 39.6±15.0 days and 35 days, respectively, in the AeEN group, and 
were 41.2±12.0 days and 38 days, respectively, in the IeEN group. These values were 
not significantly different between the groups. Postoperative complications were 
observed in four (40%) among the 10 patients in the AeEN group; anastomotic leaks 
developed in three patients (30%) and surgical site infections (SSI) developed in three 
patients (30%). Four (40%) of the 10 patients in the IeEN group also developed 
postoperative complications; anastomotic leaks in developed in three (30%), a SSI 
developed in one (10%) and a pulmonary complication occurred in one (10%) patient. No 
differences were observed in the incidences of postoperative complications between the 
groups. 
 
Discussion 
 
It is commonly considered that the preoperative use of IeNs including arginine, 
glutamine, omega-3-polyunsaturated fatty acids, nucleotides and other factors, 
increase the immune response, decrease the postoperative complications and improve 
the patient outcomes after elective gastrointestinal surgery (1-4). According to the 
 8 
consensus recommendations of the ASPEN, the preoperative use of IeNs at a dose of 
1,200~1,500 ml/day for five to seven days offers a benefit for patients undergoing an 
elective gastrointestinal surgery, such as esophagectomy (6). At the end of the 
recommendations, a list of the immune-enhancing formulas is provided. In the ESPEN 
guidelines on enteral nutrition, the perioperative management is focused on the ERAS. 
In those guidelines, the preoperative use of IeNs for five to seven days is recommended 
for cancer patients undergoing major upper abdominal surgery (7).  
The Impact® formula includes arginine, omega-3-polyunsaturated fatty acids and 
nucleotides, and it is specialized as an immune-enhancing diet. There were two trials 
comparing Impact® with the conventional enteral nutrients contained in Osmolite®. In 
critically-ill patients in the ICU, the use of Impact® increased the immune response, 
however it did not shorten the length of hospital stay (14). In postoperative 
gastrointestinal cancer patients, the use of Impact® improved the immune function, 
and reduced the incidence of infections and wound complications by 70% and shortened 
the length of hospitalization by 22% (15).  
  However despite the many promising findings, there are also negative data 
concerning the IeNs. A meta-analysis indicated that the arginine included in the IeNs is 
useful for patients undergoing elective surgery, but is harmful for septic patients (16). 
In the Canadian Clinical Practice Guidelines, it is noted described that the 
arginine-containing enteral products should not be used for nutritional support for 
mechanically ventilated critically-ill adult patients (17). Moreover, it was reported that 
the IeNs do not offer a clinical benefit for adult ICU patients (18). In the ESPEN 
Guidelines on Enteral Nutrition, the postoperative use of IeNs after uncomplicated 
surgery was given a C with regard to the level of recommendation (7). In short, the 
preoperative use of IeNs seems to be useful for patients undergoing elective 
gastrointestinal surgery, but there is no evidence of efficacy regarding the postoperative 
use of IeNs for patients undergoing gastrointestinal surgery or in critically-ill ICU 
patients 
It is thought considered that the use of antioxidants reduces the oxidative stress 
caused by surgery, trauma and other conditions, and thereby decreases the subsequent 
organ damage. AeEN was reported to increase the immune response in patients 
undergoing major gastrointestinal surgery (9). Anom®, an AeEN includes antioxidants 
such as catechin and proanthocyanidin, as well as arginine, omega-3-polyunsaturated 
fatty acids, and nucleotides. However, it does not include as much of these components 
as the Impact formula.    
There are negative data concerning the use of AeEN. For example, it was reported 
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that the AeEN including glutamine and an antioxidant solution did not improve the 
prognosis of burned and major trauma patients (10), and that, while an AeEN including 
antioxidants, and vitamins A, C, and E improved the blood levels of antioxidants, it did 
not improve the clinical outcomes of patients (11). According to the Canadian Clinical 
Practice Guidelines for nutritional support, glutamine-enriched formula should be 
considered for patients with severe burns and trauma, while the use of antioxidants and 
probiotics has no evidence to support its recommendation (17). In short, the use of AeEN 
seems to increase the circulating levels of the immune response markers in patients 
undergoing major gastrointestinal surgery and those with severe burns and trauma, 
but there is no evidence that it improves the clinical outcomes after such surgery, or has 
any impact on critically-ill ICU patients.   
There is controversy with regard to the method of administration and the dose of the 
nutrients. Some investigators have recommended that the supplements should be used 
only preoperatively and immediately after surgery. In the present randomized control 
trial, both the AeEN (Anom®) and the IeEN (Impact®) were administered at doses of 
750 to 800 ml/day for five days before surgery, and for seven days after surgery 
according to the standard clinical pathway at our hospital. The administration 
according to the protocols was successfully completed in both groups.  
This pilot study was designed as a small randomized trial to investigate the potential 
equivalence or advantages in terms of various clinical effects using two types of 
nutrients. We focused on the perioperative courses and surgical outcomes after 
esophagectomy for cancer. The number of cases was designed to be small to discover any 
potential statistical differences in nutritional markers, immunoinflammatory markers, 
oxidative stress markers and other markers, and in the clinical outcomes between the 
groups. Because we included only a small number of cases, the results from this trial 
could be carefully and accurately controlled. There is commonly an imbalance between 
two groups in studies involving a small number of patients, which can be attributed to 
the pre-study values. Therefore, we formulated the following regression model for our 
analyses: 
y=β0+β1(the previous value)+β2(group)+γ(the previous value)(group) 
The p-values at several time points were summarized using statistics which were 
constructed by adding β2 at those time points. The AIC method was adopted for the 
statistical analysis, in which the model better corresponding to the obtained data was 
selected. If the model indicated no differences, then those data were assumed to be 
equivalent. The equivalence of the two groups was concluded if the p-value was <0.18 
and no equivalence was considered to be present if the p-value was > 0.18, because the 
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number of patients in each group was 10. The probability of a false-positive finding in 
this AIC method was estimated to be less than 40%. 
All 20 patients could take food perorally. However, such patients are generally in a 
poor nutritional state due to their disease. Nutritional markers such as the total protein, 
transferrin and RBP levels were low before nutritional therapy (on the sixth day before 
surgery), and increased after nutritional therapy (as indicated the day before surgery). 
The efficacy in terms of improving these markers was similar between Anom® and 
Impact®. After surgery, all four nutritional markers were decreased, and then the levels 
of transferrin and RBP (rapid turn-over proteins) increased on the thirteenth day after 
surgery. Such postoperative changes in nutritional markers were similar between the 
both groups. Accordingly, both diets seem to have similar effects on the nutrition of 
patients who undergo esophagectomy.  
Concerning the immunoinflammatory markers, no differences were observed in the 
changes in the WBC, IL-6 and IL-8 levels throughout the perioperative period between 
the groups. However, the CRP level was more rapidly reduced after surgery in the IeEN 
group than in the AeEN group. With regard to the immunoinflammatory response, the 
IeEN (Impact®) seemed to be similar or slightly superior to the AeEN (Anom®) formula. 
Concerning the oxidative stress markers and the anti-oxidant capacity, no significant 
differences were observed in the changes in 8-Isoprotane and PAO throughout the 
perioperative period. However, the level of 8OHdG was suppressed throughout the 
perioperative course in the AeEN group compared to the IeEN group. Therefore, with 
regard to the anti-oxidant capacity, the AeEN (Anom®) seems to be similar or slightly 
superior to the IeEN (Impact®).  
One patient in the IeEN group developed aspiration pneumonia on the second day 
after surgery, when he underwent mini-cricothyroidectomy. In this patient, the level of 
IL-6 decreased from 794 pg/ml immediately after surgery to 388 pg/ml on the first day 
after surgery, when a tracheal tube was removed, and increased to 1,070 pg/ml on the 
second day after surgery when he was suffering from aspiration pneumonia. The SIRS 
period continued for 11 days after surgery. If this patient was excluded from the trial, 
the inflammatory markers were more equivalent between the groups. However, all 20 
cases were enrolled based on randomization and all were analyzed according to the 
intent-to-treat.      
The Impact® formula is an immune-enhancing diet including arginine, 
omega-3-polyunsaturated fatty acids and nucleotides. Omega-3-polyunsaturated fatty 
acids are considered to suppress the inflammation by competing against 
omega-6-polyunsaturated fatty acids to inhibit the production of prostaglandin E2 
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(PGE2) and leukotriene B4 (LTB4). It is also considered to suppress the inflammation 
by inhibiting NF-κB (19). Arginine has many functions, such as inhibiting bacterial 
growth, regulating T-cells and enhancing the production of the cytokines. It seems to 
suppress inflammation by means of NO (16). Nucleotides, elements of DNA, are 
considered to enhance the movement of WBCs (20). On the other hand, Anom® is 
antioxidant-enriched enteral nutritional supplement that include glutamine and 
polyphenol, while the content of arginine, omega-3-polyunsaturated fatty acids and 
nucleotides is lower than those present in the Impact® formula. Accordingly, both 
formulas seem to have strong points that differ from each other. However, no definitive 
difference was found in the postoperative changes in immunoinflammatory markers, 
oxidative stress markers or the antioxidant capacity between the diets. In addition, no 
large difference in the postoperative outcomes, such as the duration of SIRS, the 
incidence of postoperative complications and the duration of hospital stay was found 
between the groups. This pilot trial therefore suggests that AeEN (Anom®) and IeEN 
(Impact®) showed a similar potential in terms of their perioperative effects for patients 
undergoing esophagectomy for cancer. 
 
Conclusions 
 
  This pilot study suggested that the antioxidant-enriched enteral nutrition (Anom®) 
and the immune-enhancing enteral nutrition (Impact®)showed similar effects on 
nutrition, the immunoinflammatory reaction, the oxidative stress and on clinical 
outcomes after esophagectomy for cancer when used perioperatively. Further, large- 
scale studies are now warranted to determine whether these findings can be 
generalized to wider populations. 
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Figure legends 
Figure 1. The dosing protocol for the enteral supplements 
The AeEN (Anom®) group: 4,000 ml (800 ml/day×5days) before surgery + 8,400 ml (400~1,600 
ml/day) after surgery 
The IeEN (Impact®) group: 4,000 ml (750 ml/day×4days + 1,000 ml/day×1day) + 8,500 ml 
(500~1,500 ml/day) after surgery 
 
Figure 2. The perioperative changes in the body weight and body mass index 
  The initial p-value was calculated using the Wilcoxon-Mann-Whitney test, and other p-values, 
including the summary p-value, were calculated according to the Akaike Information Criterion.  
 *A statistically significant difference was defined as being less than 0.18 according to the statistical 
methods employed. 
 
Figure 3. The perioperative changes in nutritional markers 
   
Figure 4. The perioperative changes in inflammatory markers 
  
Figure 5. The perioperative changes in oxidative stress markers and the antioxidant capacity 
   
 
Table 1 Contents/100ml
AeEN (Anom®) IeEN (Impact®)
Arginine (g) 0.46 1.28
Antioxidant (mg)
(Polyphenol)
Catechin 35
Proanthocyanidin  20 -
ω3/ω6* 0.5 1.3
Glutamine (g) 0.75 -
Nucleotide (g) 0.013 0.129
Calorie (Kcal) 100 100
*: ratio of the omega-3-polyunsaturated fatty acid to the omega-6-polyunsaturated fatty acid
Protein (g) 5.0 5.6
Fat (g) 2.8 2.8
Carbohydrate (g) 14.0 13.4
Vitamins
C (mg) 100 9.5
E (mg) 5.0 0.67
Minerals
Others A, B1, B2, B6, B12, D, K2, niacin, pantotheniac acid, folic acid
Zn (mg) 1.5 0.67
Cu (mg) 0.15 0.12
Se (μg) 5.0 3.3
Cr (μg) 6.0 2.0
Others Na, Cl, K, Ca, Mg, P, Fe, I, Mn
Table2 Patients’ Background
ns: no significant difference, #: on admission, *1: Chronic obstructive pulmonary 
diseases (FEV1.0<2,000 ml), *2: chronic viral hepatitis or alcoholic liver disease 
assessed as more than grade I with 99mTc-GSA scintigraphy, 
*3: Diabetes requiring medication, *4: Atrial fibrillation, *5: UICC (2009)
Co-morbidities
Diet
Clinical T-stage
Clinical N-stage
Clinical stage*5
Pathological T-stage
Pathological N-stage
Pathological stage*5
Residual tumor*5
Clinical M-stage
Pathological M-stage
AeEN (Anom®)
n = 10
IeEN (Impact®)
n = 10 p- value
67±5 65±7Age ns
8:2 10:0Sex (Male : Female) ns
55±11 58±8Body weight (kg)# ns
21.1±3.3 21.1±3.3Body mass index# ns
9/0/1 7/1/2Normal/gruel/liquid ns
1 2Diabetes mellitus*3 ns
0 1 *4Cardiac diseases ns
3 4Liver dysfunction*2 ns
1 0Pulmonary diseases*1 ns
3/1/6/0 2/2/4/2pStage I/II/III/IV ns
3/0/7/0 2/0/8/0cT1/T2/T3/T4 ns
2/3/4/1 3/2/4/1cN0/N1/N2/N3 ns
2/1/7/0 2/1/4/3cStage I/II/III/IV ns
10/0 8/2R0/R1 ns
10/0 7/3cM0/M1-Lym ns
10/0 8/2pM0/M1-Lym*5 ns
3/1/5/1/0 2/1/4/2/1pT1/T2/T3/T4a/T4b ns
3/2/3/2 6/0/2/2pN0/N1/N2/N3 ns
Table 3 Surgical Procedures and Perioperative Outcomes
ns: no significant difference, SIRS: systemic inflammatory response syndrome,  
SSI: :surgical site infection, *1: Transthoracic esophagectomy (TTE), *2: Gastric 
conduit, *3: No patient received blood transfusion perioperatively, *4: minor leak 
spontaneously healed, *5: aspiration pneumonia requiring mini-cricothyroidotomy
Approach*1
Lymphadenectomy
Route of esophageal reconstruction*2
SIRS  (days)
Hospital stay
Operating duration (min)
Thoracoscopic/open
2-field/3-field
Bleeding amount (g)*3
Subcutaneous/retrosternal
Anastomotic leak*4
Postoperative complications
SSI
Pulmonary complication
mean
median
mean
median
AeEN (Anom®)
n = 10
612±90
2/8
3/7
466±353
9/1
3 (30%)
4 (40%)
3 (30%)
0
1.8±1.5
1
39.6±15.0
35
IeEN (Impact®)
n = 10
585±80
2/8
0/10
405±167
10/0
3 (30%)
4 (40%)
1 (10%)
1 (10%)*5
3.4±3.5
1
41.2±12.0
38
p- value
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
Figure 1 Regimen of enteral supplements 
Preop: 5 days (the 6th to 2nd day before
surgery),  perorally
Postop: 7 days (the 3rd to 9th day after
surgery), perenterally
0 1 2 3 4 5 6 7 8 9 10-1-3 -2-7 -6 -5 -4
Esophagectomy
5%Glucose
250 ml,
perenterally
15.0
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7preOD 1preOD 1POD 3POD 7POD 13POD
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7preOD 1preOD 1POD 3POD 7POD 13POD
Body weight
Figure 2 Body Weight and Body Mass Index (BMI)
Kg
Kg/m2
AeEN
(Anom®)
IeEN
(Impact®)
*: p<0.18
AeEN 55.1±11.0 53.8±10.3 55.7±9.9 54.6±10.1 53.4±9.8 52.3±9.6 
IeEN 57.5±8.6 56.3±8.2 58.1±9.0 56.9±8.1 55.4±8.3 55.3±7.9 
P-value 0.623 0.523 0.761 0.983 0.531 0.039
Summary
P=0.804
Summary
P=0.721
AeEN 21.1±3.3 20.6±3.1 21.4±2.9 21.0±3.1 20.5±3.0 20.1±2.8 
IeEN 21.1±3.3 20.7±3.2 21.3±3.4 20.9±3.1 20.4±3.1 20.3±3.0 
P-value 0.910 0.692 0.615 0.921 0.518 0.065
*
*
*
*
4.0
5.0
6.0
7.0
8.0
7 PreOD 1 PreOD 7 PostOD 13 PostOD
Total protein 
2.0
2.5
3.0
3.5
4.0
4.5
7 PreOD 1 PreOD 7 PostOD 13 PostOD
Albumin
100
150
200
250
300
7 PreOD 1 PreOD 7 PostOD 13 PostOD
Transferrin
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7 PreOD 1 PreOD 7 PostOD 13 PostOD
Retinol binding protein
g/dl g/dl
mg/dl mg/dl
Figure 3 Nutritional markers
*
*
*
*
*
AeEN
(Anom®)
IeEN
(Impact®)
*: p<0.18
Summary
p=0.371
*
*
Summary
p=0.446
*
Summary
p=0.988
Summary
p=0.697
*
*
*
*
AeEN 3.77±0.25 3.89±0.20 3.06±0.32 3.07±0.36 
IeEN 3.50±0.47 3.75±0.54 3.04±0.49 2.96±0.57 
P-value 0.149 0.933 0.840 0.609
AeEN 4.3±0.9 4.8±0.7 2.8±1.1 4.0±1.7 
IeEN 3.5±1.2 4.3±1.2 2.9±1.1 3.8±1.8 
P-value 0.480 0.746 0.193 0.356
AeEN 223±38 242±44 147±36 184±46 
IeEN 213±29 237±36 166±38 189±54 
P-value 0.393 0.409 0.053 0.072
AeEN 6.71±0.44 6.91±0.44 5.99±0.22 6.50±0.46 
IeEN 6.21±0.56 6.58±0.61 6.13±0.50 6.22±0.57 
P-value 0.085 0.938 0.165 0.103
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Figure 4 Inflammatory markers
/μｌ
pg/mｌ
pg/mｌ
mg/dｌ
*
*
*
*
*
*
AeEN
(Anom®)
IeEN
(Impact®)
*: p<0.18
AeEN 56±11 61±15 83±21 77±21 77±11 98±28
IeEN 63±15 64±15 77±17 80±20 86±13 81±35
P-value 0.424 0.399 0.110 0.228 0.107 0.179
*
*
Summary
p=0.274
Summary
p=0.115 *
AeEN 324±185 147±75 72±34
IeEN 398±292 281±237 177±316
P-value 0.529 0.150 0.588
Summary
p=0.195
Summary
p=0.909
*
*
AeEN 0.4±0.6 11.4±2.8 17.9±7.5 9.5±7.2 7.2±10.4
IeEN 0.5±0.8 12.1±4.0 17.5±4.9 6.4±3.8 3.4±3.6
P-value 0.469 0.879 0.446 0.102 0.719
AeEN 54.7±30.9 22.1±13.2 22.8±18.3
IeEN 54.5±48.9 23.5±16.7 24.3±31.1
P-value 0.738 0.787 0.967
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8‐OHdG in urine
400
500
600
700
800
900
1000
1100
1200
7 PreOD 1 PreOD 2 PostOD 13 PostOD
PAO 
(Potential antioxidant)
20
70
120
170
220
270
320
370
420
7 PreOD 1 PreOD 2 PostOD 13 PostOD
8‐Isoprostane in urine
Figure 5 Oxidative stress and antioxidant capacity
pg/mg Cre pg/mg Cre
μmol/L
AeEN 10.1±7.0 10.8±6.2 11.4±8.5 14.7±5.4
IeEN 12.5±4.7 16.5±5.7 11.7±5.7 19.7±6.5
p‐value 0.203 0.022 0.780 0.078
*
*
*
*
Summary
p=0.058 *
AeEN 130±64 137±41 184±104 183±97
IeEN 174±59 205±78 219±85 207±91
P-value 0.041 0.051 0.983 0.981
*
*
*
*
Summary
p=0.409
AeEN 980±154 918±177 679±135 731±117
IeEN 965±131 1028±223 632±120 666±82
P-value 0.954 0.108 0.319 0.209
Summary
p=0.499
AeEN
(Anom®)
IeEN
(Impact®)
*: p<0.18
*
*
